BSD City, November 4rd, 2025 – Contract research organizations (CROs) are essential components of the healthcare innovation ecosystem—supporting pharma, biotech, medtech companies, and academic institutions in conducting research and testing on new therapies and medical devices. The development of CROs is in line with the priorities of the Ministry of Health of the Republic Indonesia as the demand for high-quality, efficient, and globally standardized clinical research continues to rise. According to the Indonesia Contract Research Organization Market report published by 6Wresearch, the Contract Research Organization (CRO) market in Indonesia is projected to reach USD 1 billion by 2030, growing at a CAGR of 10.6% from 2024.
Recognizing this potential, Living Lab Ventures (LLV), the corporate venture capital arm of Sinar Mas Land, officially announced a strategic investment in the Indonesia Institute for Clinical Research and Scientific Exploration (INCREASE) Laboratorium Indonesia, a rapidly growing clinical research company that provides world-class clinical trial conduct and laboratory services. The funding will be used to expand operations, strengthen research outcomes, and accelerate INCREASE’s global network.
Headquartered in the Biomedical Campus within the D-HUB Special Economic Zone (D-HUB SEZ) in BSD City, INCREASE delivers fully integrated, end-to-end clinical research solutions encompassing study design, execution, regulatory affairs, and both clinical and bioanalytical laboratory testing. Backed by extensive operational experience, deep regulatory insight, a vast network, a strong professional talent base, and advanced laboratory infrastructure, INCREASE is ready to stand out as a trusted partner for global-standard research execution. Its comprehensive capabilities position the company to accelerate healthcare innovation, enhance time-to-market efficiency, and capture growing demand within Indonesia’s rapidly expanding life sciences sector.
Bayu Seto, Partner of Living Lab Ventures, said, “This investment reflects LLV’s broader commitment to accelerating growth in Indonesia’s healthcare sector, one of the country’s most promising and fastest-growing industries, as demand for advanced clinical research infrastructure and regional health resilience continues to grow. Indonesia has the potential to become a regional powerhouse in health and biomedicine, and we see INCREASE as a strategic platform that can catalyze the national clinical research ecosystem, attract global partners, and enhance the future competitiveness of Indonesia’s healthcare sector.”
This investment is part of LLV’s long-term strategy to support high-priority sectors with global scalability, including healthcare, technology, and education. With the integration of technologies like IoT and AI, and a growing focus on major therapeutic areas such as oncology and infectious diseases, Indonesia is becoming an increasingly strategic location for internationally recognized clinical research development.
Mulyawan Gani, CEO of Digital Business at Sinar Mas Land, explained, “As demand grows for healthier, longer lives, the health sector is becoming central to future development. INCREASE’s presence in BSD City strengthens the research and education ecosystem we are building and brings Indonesia closer to the world’s leading medical innovation hubs. This investment reflects our belief that the convergence of science, technology, and infrastructure will be key to placing Indonesia on the global medical innovation map, and that Sinar Mas Land through BSD City is ready to lead that transformation.”
On the same occasion, dr. Robby Hertanto, Chief Executive Officer of INCREASE, added,“We are honored to receive LLV’s trust and investment. This investment is more than capital, it is evidence of our shared commitment to advance healthcare innovation and build Indonesia’s role as a global hub for world-class clinical research. With LLV’s strategic support and ecosystem network, we aim to accelerate scientific discovery, nurture local talent, and create meaningful impact that extends beyond borders. Together, we are shaping the future of the Indonesian healthcare ecosystem through collaboration, innovation, and purpose-driven growth.”
INCREASE has also forged strategic partnerships with Tsinghua University (China) and The University of Osaka (Japan) to advance research and development in healthcare innovation. These collaborations combine global academic excellence with INCREASE’s growing research capabilities to accelerate the translation of scientific breakthroughs into practical healthcare solutions. The partnerships also include joint research programs, technology transfer, and manpower training initiatives aimed at nurturing local expertise and strengthening Indonesia’s biomedical research ecosystem.
Currently, INCREASE is executing multiple projects with clients from Indonesia, Singapore, Australia, and China. The demonstrates its growing reputation as a trusted regional partner for high-quality clinical research. In line with its commitment to global standards, INCREASE is also pursuing international certifications, including the College of American Pathologists (CAP), ISO 9001:2015, ISO 17025:2017, and ISO 15189:2022 to further enhance its operational credibility, quality assurance, and competitiveness in the global clinical research landscape. (*)
